When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BMY - Amgen to acquire Celgene's Otezla for $13.4B
Bristol-Myers Squibb Company
Amgen (NASDAQ:AMGN) has agreed to acquire global rights to Celgene's (NASDAQ:CELG) psoriasis med Otezla (apremilast) for $13.4B in cash. Bristol-Myers Squibb (NYSE:BMY) is divesting the PDE4 inhibitor in order to receive regulatory sign-off on its merger with Celgene. The transaction is contingent on the FTC's blessing on the merger, its closing and satisfaction of other closing conditions.
More news on: Amgen Inc., Celgene Corporation, Bristol-Myers Squibb Company, Healthcare stocks news, Stocks on the move, Merger & acquisition news,